Targeting the MiR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-small Cell Lung Cancer Cells Harboring EMT Features

Overview

Journal Sci Rep

Specialty Science

Date 2017 Jan 14

PMID 28084458

Citations 37

Authors

Hiroki Sato

Kazuhiko Shien

Shuta Tomida

Kazuhiro Okayasu

Ken Suzawa

Shinsuke Hashida

Hidejiro Torigoe

Mototsugu Watanabe

Hiromasa Yamamoto

Junichi Soh

Hiroaki Asano

Kazunori Tsukuda

Shinichiro Miyoshi

Shinichi Toyooka

Affiliations

Soon will be listed here.

Abstract

MicroRNA (miR)-200 family members (miR-200s) are frequently silenced in advanced cancer and have been implicated in the process of epithelial-to-mesenchymal transition (EMT). We previously reported that miR-200s were silenced through promoter methylation in acquired EGFR-tyrosine kinase inhibitor (TKI) resistant non-small cell lung cancer (NSCLC) cells harboring EMT features. In this study, we examined the functional role of miR-200s in NSCLC cells and investigated a novel approach to overcoming acquired EGFR-TKI resistance. In the analysis of NSCLC cell lines, each of the miR-200s expression-silenced cell lines showed promoter methylation. Significant correlations between miR-200c silencing and several oncogenic pathway alterations, including EMT-changes and LIN28B overexpression, were observed in the database analysis. In addition, EGFR-wild type cell lines had lower miR-200s expression levels than EGFR-mutant cell lines. The introduction of miR-200c using pre-miR-200c caused LIN28B suppression in cells with acquired EGFR-TKI resistance that harbored EMT features. Interestingly, both the introduction of miR-200c and the knockdown of LIN28B produced an antitumor effect in acquired EGFR-TKI resistance cells, whereas these manipulations were not effective in parental cells. The miR-200c/LIN28B axis plays an important role in cells with acquired resistance to EGFR-TKI that harbor EMT features and might be a useful therapeutic target for overcoming resistance.

Citing Articles

Diagnostic value of microRNA-200 expression in peripheral blood-derived extracellular vesicles in early-stage non-small cell lung cancer.

Liu L, Zhang F, Niu D, Guo X, Lei T, Liu H Clin Exp Med. 2024; 24(1):214.

PMID: 39249157 PMC: 11384644. DOI: 10.1007/s10238-024-01455-4.

The role of LIN28B in tumor progression and metastasis in solid tumor entities.

Gewalt T, Noh K, Meder L Oncol Res. 2023; 31(2):101-115.

PMID: 37304235 PMC: 10208000. DOI: 10.32604/or.2023.028105.

Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the -ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells.

Vad-Nielsen J, Staunstrup N, Kjeldsen M, Dybdal N, Flandin G, De Stradis C Transl Lung Cancer Res. 2023; 12(1):42-65.

PMID: 36762066 PMC: 9903082. DOI: 10.21037/tlcr-22-507.

The significance of the crosstalk between ubiquitination or deubiquitination and ncRNAs in non-small cell lung cancer.

Sun Y, He P, Li L, Ding X Front Oncol. 2023; 12:969032.

PMID: 36727069 PMC: 9884829. DOI: 10.3389/fonc.2022.969032.

Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics.

Jo H, Shim K, Jeoung D Int J Mol Sci. 2022; 23(11).

PMID: 35682560 PMC: 9180509. DOI: 10.3390/ijms23115881.

References

Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D . Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009; 138(3):592-603. PMC: 2731699. DOI: 10.1016/j.cell.2009.07.011. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Takeyama Y, Sato M, Horio M, Hase T, Yoshida K, Yokoyama T . Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 2010; 296(2):216-24. PMC: 3110825. DOI: 10.1016/j.canlet.2010.04.008. View

Shien K, Ueno T, Tsukuda K, Soh J, Suda K, Kubo T . Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers. Clin Lung Cancer. 2012; 13(6):488-93. DOI: 10.1016/j.cllc.2012.02.003. View

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H . Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11):3753-6. DOI: 10.1158/0008-5472.CAN-04-0637. View

Shien K, Yamamoto H, Soh J, Miyoshi S, Toyooka S . Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. Acta Med Okayama. 2014; 68(4):191-200. DOI: 10.18926/AMO/52785. View

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y . Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012; 77(1):162-7. DOI: 10.1016/j.lungcan.2012.02.006. View

10.

Piskounova E, Polytarchou C, Thornton J, LaPierre R, Pothoulakis C, Hagan J . Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011; 147(5):1066-79. PMC: 3227872. DOI: 10.1016/j.cell.2011.10.039. View

11.

Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu K . Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013; 73(10):3051-61. PMC: 4506773. DOI: 10.1158/0008-5472.CAN-12-4136. View

12.

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-8. PMC: 2757943. DOI: 10.1038/ng.392. View

13.

Medina P, Slack F . microRNAs and cancer: an overview. Cell Cycle. 2008; 7(16):2485-92. DOI: 10.4161/cc.7.16.6453. View

14.

Angelucci A, Gravina G, Rucci N, Millimaggi D, Festuccia C, Muzi P . Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer. 2006; 13(1):197-210. DOI: 10.1677/erc.1.01100. View

15.

Bishop J, Benjamin H, Cholakh H, Chajut A, Clark D, Westra W . Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010; 16(2):610-9. DOI: 10.1158/1078-0432.CCR-09-2638. View

16.

Ramirez R, Sheridan S, Girard L, Sato M, Kim Y, Pollack J . Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004; 64(24):9027-34. DOI: 10.1158/0008-5472.CAN-04-3703. View

17.

Landi M, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen A . MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010; 16(2):430-41. PMC: 3163170. DOI: 10.1158/1078-0432.CCR-09-1736. View

18.

Hsu K, Shen M, Huang Y, Cheng Y, Lin S, Chow N . Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015; 113(3):414-24. PMC: 4522643. DOI: 10.1038/bjc.2015.254. View

19.

Witta S, Gemmill R, Hirsch F, Coldren C, Hedman K, Ravdel L . Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66(2):944-50. DOI: 10.1158/0008-5472.CAN-05-1988. View

20.

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View